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Sudden Cardiac Death in Patients With Coronary
Disease and Left Ventricular Ejection Fraction >35%
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Objectives The aim of this study was to determine whether single-photon emission computed tomography (SPECT) myocar-
dial perfusion imaging (MPI) is an effective method of risk stratification for sudden cardiac death (SCD) in pa-
tients with coronary artery disease (CAD) and left ventricular ejection fraction (LVEF) 35%.
Background Most victims of SCD have an LVEF 35%.
Methods The study population included 4,865 patients with CAD and LVEF 35% who underwent gated SPECT MPI. We
used Cox proportional hazard modeling to examine the relationship between patient characteristics and SCD.
Results The median age of the population was 63 years (25th, 75th percentile: 54, 71 years), and the median LVEF was 56%
(25th, 75th percentile: 50%, 64%). The median follow-up for all patients was 6.5 years (25th, 75th percentile: 3.6, 9.3
years). During follow-up, there were 161 SCDs (3.3%). After multivariable adjustment, LVEF, the Charlson index, hyper-
tension, smoking, antiarrhythmic drug therapy, and the summed stress score (SSS) were associated with SCD (all
p  0.05). For each 3-U increase in the SSS, the hazard ratio for SCD was 1.13 (95% confidence interval: 1.04 to
1.23). The addition of perfusion data to the clinical history and LVEF was associated with increased discrimination for
SCD events (c-index 0.728). Risk stratification with a derived SPECT nomogram did not result in statistically signifi-
cant net reclassification improvement (p  0.26) or integrated discrimination improvement (p  0.38).
Conclusions Among patients with CAD and LVEF 35%, the extent of stress MPI perfusion defects is associated with an in-
creased risk of SCD. Future large prospective studies should address the role of perfusion imaging in the identifi-
cation of high-risk patients with LVEF 35% who might benefit from ICD implantation. (J Am Coll Cardiol
2010;56:206–14) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.061e
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Elthough our treatment of coronary artery disease (CAD)
as improved, and age-adjusted mortality due to cardiovas-
ular disease is declining, over 60% of all cardiovascular
eath is sudden (1). The implantable cardioverter-
efibrillator (ICD) is highly efficacious in the prevention of
udden cardiac death (SCD); however, its utility in clinical
ractice is dependent upon identifying those patients who
re at greatest risk (2,3). Although the left ventricular
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tratification of SCD, the majority of SCD victims have
reserved left ventricular (LV) systolic function (4,5).
See page 215
Given the magnitude of SCD events in patients with an
VEF 35%, there is a great need to identify risk factors in
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July 13, 2010:206–14 SPECT and Sudden Death With LVEF >35%his population; unfortunately, little is known about the pre-
ictors of SCD in patients with LVEF35%. The objective of
his analysis was to determine whether myocardial perfusion
efects, observed via single-photon emission computed tomogra-
hy (SPECT) myocardial perfusion imaging (MPI), are associ-
ted with the occurrence of SCD in patients with LVEF35%.
ethods
o identify clinical and SPECT MPI variables associated
ith SCD in patients with CAD and LVEF 35%, we
onducted an observational study of patients in the Duke
atabank for Cardiovascular Disease (DDCD). The
DCD includes the past medical history and clinical course
f over 81,800 cardiovascular patients in the Duke Univer-
ity Health System. A prospective, longitudinal record is
stablished for each patient with angiographically significant
AD. Finally, an emphasis is placed on annual follow-up,
ajor clinical events, and cause-specific death.
tudy population. Between January 1993 and December
006 we identified 4,865 patients with CAD and LVEF
35% who underwent SPECT stress-rest MPI. All patients
ad CAD (75% stenosis of 1 or more major epicardial
oronary arteries) documented by coronary angiography within
80 days of their MPI study. In the event that a patient
nderwent multiple MPIs, only the most recent study was
ncluded in the analysis. Patients with incomplete angiographic
ata, adult congenital heart disease, primary valvular heart
isease, or an ICD were excluded.
ollow-up and outcomes. The primary end point in this
nalysis was SCD. SCD was adjudicated using the previously
alidated modified Hinkle-Thaler classification system (6–8)
nd SCD was strictly defined as death within 1 h of symptom
nset, or an unobserved death in which the patient was seen
nd known to be doing well within 24 h of death. Survivors of
borted SCD or resuscitated cardiac arrest were also considered
o have experienced SCD and were included in the primary
nd point. All deaths that did not meet the criteria for SCD
ere classified as “non-sudden deaths,” including noncardiac
eaths. An independent clinical events committee reviewed
nd classified all deaths without knowledge of the clinical data
r MPI results. Follow-up was 96% complete.
linical information. Demographic and clinical characteris-
ics were recorded prospectively at the time of coronary
ngiography (9,10). Prospectively collected variables included:
ge, sex, race, LVEF, hypertension, diabetes, history of heart
ailure, New York Heart Association (NYHA) functional
lassification, CAD severity as reflected by the number of
iseased vessels, prior myocardial infarction, prior revascular-
zation, peripheral vascular disease, renal insufficiency (chronic
idney disease stage 3; estimated glomerular filtration rate
60 ml/min), smoking history, chronic obstructive pulmonary
isease, hyperlipidemia, presence of carotid bruits, ventricular
3 gallop, and a modified Charlson comorbidity index (11). A
istory of myocardial infarction and heart failure were removed
rom the Charlson index and examined independently, given rheir known associations with
CD. When multiple imaging
odalities were used to assess LV
unction, the following hierarchy
f LVEF assessment was used:
PECT (n  1,678)  echocar-
iography (n  477)  ventricu-
ography at cardiac catheterization
n  2,724). Use of baseline beta-
lockers and antiarrhythmic med-
cations were incorporated for ad-
ustment in the multivariable
nalysis.
tress testing and SPECT imag-
ng. Patients capable of exercise un-
erwent treadmill stress testing with
he Bruce protocol, unless an alter-
ative protocol was requested by the
rdering physician. Patients unable
o exercise underwent pharmaco-
ogic stress testing. The SPECT
PI was performed according to
he previously described Duke Uni-
ersity nuclear laboratory protocol
12,13). In brief, SPECT images
ere obtained with multi-head de-
ectors with 30 s/projection at rest
nd 20 s/projection during stress.
he studies were independently in-
erpreted by 3 nuclear cardiologists
n our laboratory without attenua-
ion correction. All suboptimal stud-
es were repeated. Either the Cedars Sinai QGS/QPS (Los
ngeles, California) or Emory Toolbox software (Atlanta, Geor-
ia) programs were used to determine the gated SPECT LVEF.
f the nuclear imaging study could not provide LVEF because of
ating problems, LVEF data were obtained from other sources.
The SPECT MPI studies were evaluated independently
ith relative perfusion recorded in each myocardial segment
0  no defect, 1  mild defect, 2  moderate defect, and
 severe defect). A cumulative perfusion score during
tress, the summed stress score (SSS), was calculated by
dding the perfusion scores in all myocardial segments.
ccordingly, the SSS incorporates both fixed and reversible
efects and would equal 0 in a normal study. The SSS is an
stablished predictor of cardiovascular outcomes, including
yocardial infarction and CV death (14–18). The summed
est score (SRS), which is the sum of the perfusion scores in
ll segments at rest (fixed defects), and the summed differ-
nce score (SDS), which is the sum of the differences
etween the stress and rest perfusion scores (reversible
efects), were also determined for each patient using an
dentical scoring system.
At the time these data were collected we used a 12-
egment model. We have subsequently reported an algo-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
DDCD  Duke Databank for
Cardiovascular Disease
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
IDI  integrated
discrimination improvement
LV  left ventricle/ventricular
LVEF  left ventricular
ejection fraction
MPI  myocardial perfusion
imaging
NRI  net reclassification
improvement
NYHA  New York Heart
Association
SCD  sudden cardiac
death
SDS  summed difference
score
SPECT  single-photon
emission computed
tomography
SRS  summed rest score
SSS  summed stress
scoreithm for conversion of 12-segment perfusion scores to
1
i
t
S
a
d
c
p
a
w
p
c
r
i
p
c
p
o
p
j
S
o
i
m
b
t
c
n
a
w
d
S
b
d
d
d
p
s
F
t
d
d
S
l
D
R
O
y
p
p
u
t
y
t
T
w
P
t
w
p
p
m
p
d
B
D
208 Piccini et al. JACC Vol. 56, No. 3, 2010
SPECT and Sudden Death With LVEF>35% July 13, 2010:206–147-segment scores, which is highly correlated to visual
nterpretation by the 17-segment model with nearly iden-
ical prognostic information (19).
tatistical analysis. Clinical characteristics were examined
ccording to the primary end point (SCD, nonsudden
eath, and alive at last contact) with percentages for
ategorical variables and medians with 25th and 75th
ercentiles for continuous variables. The occurrence of SCD
s a function of time after SPECT imaging was examined
ith survival analysis methods. To address competing risks,
atients who died from causes other than SCD were
ensored at the time of death. Cox proportional hazards
egression modeling was used to identify factors that were
ndependently associated with SCD. Unadjusted Cox pro-
ortional hazards SCD models were also generated for all
andidate variables, including the baseline characteristics,
erfusion indexes, and LVEF. After examining the results
f a flexible Cox model-fitting approach involving cubic
olynomial spline functions (20), the linearity of the unad-
usted relationship between each continuous variable and
CD was assessed. When nonlinear relationships with
utcomes were identified, variable transformations were
mplemented to satisfy this model assumption. Unadjusted
odels were also examined to explore the relationship
etween beta-blockers, antiarrhythmic drugs, and SCD.
Significant variables were determined with stepwise selec-
ion (and backwards elimination) at p  0.05 from the
andidate variable list that included baseline characteristics,
uclear perfusion scores, LVEF, use of beta-blockers, and
ntiarrhythmic pharmacotherapy. The c-index was calculated
ith Cox survival methods for the final model to evaluate the
iscriminatory accuracy of the model for the occurrence of
CD. The final SCD model was internally validated with a
ootstrap resampling technique. One hundred samples were
rawn at random with replacement. A model c-index was
erived for each sample, and mean c-indexes with 95% confi-
ence intervals (CIs) were calculated. The variable selection
rocess was applied to each sample, and the number of times
ignificant variables stayed in the final model were reported.
ormal risk reclassification analyses were conducted with both
he net reclassification improvement (NRI) and integrated
iscrimination improvement (IDI) methods (21).
All tests were 2-tailed, and statistical significance was
eclared at alpha 0.05. All analyses were performed with
AS software version 8.2 (SAS Institute, Cary, North Caro-
ina). The study protocol was reviewed and approved by the
uke University Medical Center Institutional Review Board.
esults
utcomes. The median follow-up for all patients was 6.5
ears (25th, 75th percentile: 3.6, 9.3 years). Among 4,865
atients with CAD and an LVEF 35%, 161 (3.3%)
atients died suddenly (77 [48%] witnessed, 60 [37%]
nobserved, and 24 [15%] after resuscitation). The median
ime to SCD was 3.0 years (25th, 75th percentile: 1.3, 6.2
a
cears). There were 1,557 (32%) deaths other than SCD. Of
he 1,557 deaths other than SCD, 789 were cardiac deaths.
he median follow-up in those patients alive at last contact
as 7.2 years (25th, 75th percentile: 4.9, 10.2 years).
atient characteristics. The baseline characteristics are de-
ailed in Table 1. Most of the cohort was male (67%), and 16%
ere black or African American. The median age of those
atients with SCD was 62 years. Although we included
atients with an LVEF 35%, among those with SCD, the
edian LVEF was 51%, and the vast majority of patients had
reserved LV function (25th, 75th percentile: 43, 60). The
istribution of the LVEF, Charlson comorbidity index, and
aseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
SCD
(n  161)
Death Other
Than SCD
(n  1,557)
Alive at
Last Contact
(n  3,147)
Age, yrs 62 (54–72) 68 (60–74) 60 (52–69)
Male 68.9 62.2 69.0
Black/African American 20.5 16.4 15.9
EF 51 (43–60) 55 (47–63) 57 (51–65)
Summed stress score 8 (4–13) 6 (2–11) 5 (2–10)
Summed rest score 4 (0–8) 2 (0–6) 1 (0–5)
Summed difference score 3 (0–6) 2 (0–5) 2 (0–5)
Hypertension 78.3 73.0 66.1
Diabetes 40.4 39.8 26.6
Heart failure severity
No heart failure 77.6 75.1 89.6
NYHA functional class I 5.0 4.5 1.5
NYHA functional class II 5.6 6.7 4.4
NYHA functional class III 6.8 8.2 3.3
NYHA functional class IV 5.0 5.5 1.2
CAD severity
1-vessel disease 27.3 29.6 40.8
2-vessel disease 31.7 25.7 27.2
3-vessel disease 41.0 44.7 32.0
Medical history
Prior PCI 30.4 30.9 37.3
Prior CABG 36.6 35.8 28.4
Prior myocardial infarction 47.8 45.8 39.2
Cerebrovascular disease 20.5 19.7 10.3
Peripheral vascular disease 23.6 20.6 10.1
Renal insufficiency 5.6 4.8 1.4
Smoking history 72.0 64.8 59.6
Chronic obstructive
pulmonary disease
11.8 14.8 5.5
Hyperlipidemia 67.7 60.3 68.4
Charlson comorbidity (2) 33.5 35.3 15.8
Physical examination
Carotid bruits 19.4 20.8 8.4
S3 gallop 2.5 2.4 1.1
Medications
Aspirin 61.5 62.1 61.2
ACE inhibitor 39.1 42.1 45.1
Beta-blocker 41.7 47.4 45.4
Antiarrhythmic 6.0 3.5 2.3
ata shown are median (interquartile range) or %.
ACE angiotensin-converting enzyme; CABG coronary artery bypass grafting; CAD coronary
rtery disease; EF  ejection fraction; NYHA  New York Heart Association; PCI  percutaneous
oronary intervention; SCD  sudden cardiac death.
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July 13, 2010:206–14 SPECT and Sudden Death With LVEF >35%SS in the study population are shown in Figure 1. Further-
ore, 1 in 4 patients with SCD had a diagnosis of heart
ailure. The median SSS was greatest, 8 (25th, 75th percentile:
, 13), in those patients with SCD, compared with 6 (25th,
5th percentile: 2, 11) in those who experienced death other
han SCD, and 5 (25th, 75th percentile: 2, 10) in those
atients alive at last contact. Forty-eight percent of the SCD
atients had a prior MI, and 55% had prior revascularization.
mong all patients, 2,538 patients (52%) had SPECT before
oronary angiography, of which 1,713 had subsequent revas-
ularization. A total of 644 patients (13.2%) underwent
PECT within 60 days of an MI.
nadjusted time-to-event analyses. We examined the fac-
Figure 1 Distribution of Baseline Left Ventricular Function,
Degree of Comorbid Illness, and Stress Perfusion Scores
Histograms depicting the distribution of (A) left ventricular ejection fraction,
(B) Charlson index, and (C) summed stress scores in the study population.ors associated with SCD in unadjusted Cox models (Table 2).
C
dn this cohort with LVEF35%, age, sex, and prior MI were
ot associated with the occurrence of SCD. The presence of
ypertension, higher NYHA functional classification, CAD
everity, cerebrovascular disease, peripheral vascular disease,
moking, diabetes, renal disease, and declining LVEF were all
ssociated with an increased hazard of SCD. Additionally, the
resence of comorbid medical illness (as reflected by the
harlson index) was also associated with an increased risk of
CD. In terms of therapeutic history, beta-blocker use at
aseline and prior coronary revascularization were not associ-
ted with statistically significant reductions in the occurrence of
CD. Antiarrhythmic (Vaughan-Williams class I and III)
rug therapy was associated with an increased hazard of SCD.
n terms of MPI perfusion scores, every 3-U increase in the
SS was associated with a 23% increase in the hazard for SCD.
s shown in Figure 2, patients with an SSS 8 had a higher
umulative incidence of SCD when compared with those
atients with an SSS 8 (log-rank p  0.0001).
djusted analyses of survival free from SCD. After adjust-
ent for clinical characteristics, severity of CAD, and baseline
nadjusted Factors Associated With SCDTable 2 Unadjusted Factors Associated With SCD
Variable Name
Likelihood Ratio
Chi-Square HR (95% CI) p Value
Age 0.77 1.01 (0.99–1.02) 0.3817
Black 3.14 1.43 (0.98–2.10) 0.0766
Male 0.02 1.03 (0.74–1.43) 0.8776
Hypertension 10.88 1.82 (1.25–2.65) 0.0010
NYHA CHF severity class 9.50 1.25 (1.10–1.43) 0.0021
CAD severity (number of
diseased vessels)
5.69 1.25 (1.04–1.50) 0.0170
History of MI 0.70 1.14 (0.84–1.56) 0.4016
History of cerebrovascular
disease
6.93 1.72 (1.17–2.52) 0.0085
History of peripheral vascular
disease
11.85 1.98 (1.37–2.84) 0.0006
Smoker 4.56 1.44 (1.02–2.04) 0.0328
Renal insufficiency 9.58 3.56 (1.81–6.99) 0.0020
Body mass index 1.58 1.02 (0.99–1.04) 0.2094
History of diabetes 10.24 1.69 (1.24–2.32) 0.0014
Charlson index 24.62 1.35 (1.21–1.49) 0.0001
Carotid bruits 7.09 1.76 (1.19–2.61) 0.0078
COPD 3.22 1.59 (0.99–2.59) 0.0729
Hyperlipidemia 0.09 1.05 (0.76–1.46) 0.7620
History of angina 0.71 0.82 (0.52–1.29) 0.3994
EF (HR per 5%) 39.67 0.78 (0.72–0.85) 0.0001
Third heart sound 1.09 1.78 (0.66–4.81) 0.2961
Beta-blocker use 2.10 0.79 (0.57–1.09) 0.1469
Antiarrhythmic drug use 5.97 2.62 (1.33–5.14) 0.0145
Summed stress score
(HR per 3 U)
26.46 1.23 (1.14–1.32) 0.0001
Summed rest score
(HR per 3 U)
23.59 1.25 (1.15–1.36) 0.0001
Summed difference score
(HR per 3 U)
1.50 1.08 (0.96–1.21) 0.2110
Prior revascularization 0.18 0.94 (0.69–1.28) 0.6749
History of PCI 3.21 0.74 (0.53–1.04) 0.0734HF  congestive heart failure; CI  confidence interval; COPD  chronic obstructive pulmonary
isease; HR  hazard ratio; MI  myocardial infarction; other abbreviations as in Table 1.
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SPECT and Sudden Death With LVEF>35% July 13, 2010:206–14eta-blocker use, Cox proportional hazards modeling identi-
ed the Charlson index (hazard ratio [HR]: 1.33, 95% CI:
.19 to 1.49, p  0.0001), hypertension (HR: 1.71, 95% CI:
.17 to 2.50, p  0.006), antiarrhythmic drug therapy (HR:
.04, 95% CI: 1.04 to 4.01, p  0.039), and smoking (HR:
.42, 95% CI: 1.01 to 2.01, p  0.047) as factors associated
ith an increased hazard of SCD (Table 3). Higher LVEF
as associated with decreased risk of SCD (HR: 0.74 per
%, 95% CI: 0.66 to 0.83, p  0.0001). In terms of MPI,
3-U increase in the SSS was associated with an increased
isk of SCD (HR: 1.13, 95% CI: 1.04 to 1.23, p  0.004).
To assess the possible influence of revascularization
despite adjustment), we conducted a sensitivity analysis
estricted to those patients without post-SPECT revascu-
arization. After excluding patients with subsequent revas-
ularization (n  1,713), the SSS remained the perfusion
ndex most closely associated with SCD (HR: 1.12 per 3-U
ncrease, 95% CI: 1.01 to 1.24, p  0.034).
ignificant Multivariable Predictors of SCDn Patients With CAD and LVEF >35%Table 3 S gnific nt Multivariable Predictors of SCDin Patients With CAD and LVEF >35%
Variable
Likelihood Ratio
Chi-Square HR (95% CI) p Value
LVEF (HR per 5% 58%)* 27.08 0.74 (0.66–0.83) 0.0001
Charlson index 24.10 1.33 (1.19–1.49) 0.0001
Summed stress score
(HR per 3 U)
8.28 1.13 (1.04–1.23) 0.004
Hypertension 7.59 1.71 (1.17–2.50) 0.006
Antiarrhythmic drug
treatment
4.24 2.04 (1.04–4.01) 0.039
Smoker 3.96 1.42 (1.01–2.01) 0.047
To satisfy linearity assumption, left ventricular ejection fraction (LVEF) values58 were set to 58.
Figure 2 Cumulative Incidence of SCD According to SSS
The incidence of sudden cardiac death (SCD) was greater in those patients with a
versus an SSS 8 (log rank p  0.0001). The numbers at risk in each group are-statistic  0.728.
Abbreviations as in Tables 1 and 2. AWe also sought to determine whether the SSS provided
ncremental predictive power, when compared with the
VEF, for the occurrence of SCD. With Cox proportional
azards modeling, the addition of the SSS to the clinical
istory and LVEF led to improvement in the predictive
ower of the model as reflected by the global chi-square
ncrement (global chi-square increased from 90 to 98 [p for
ifference 0.005]; c-index 0.710 to 0.728). After inclusion
f the nuclear perfusion data, the c-index for the overall
odel improved by 0.018 (95% CI: 0.002 to 0.034). With
espect to the final model, on the basis of global likelihood
atio chi-squares, SSS accounted for 27% of the total
rognostic information, whereas LVEF accounted for 52%.
lternative causes of death. We also examined the associa-
ion between the SSS and alternative outcomes in univariate
ox models. The incremental hazard observed with the SSS
as greatest for SCD (Table 4) and exceeded that observed for
ll-cause death (HR for SCD: 1.23, 95% CI: 1.14 to 1.32, vs.
R for all-cause death: 1.09, 95% CI: 1.06 to 1.12). The SSS was
ot retained in the stepwise selection process for the final multi-
ariable model for nonsudden death and all-cause mortality.
ootstrap validation. To assess the validity and stability of
ur predictive model we conducted serial bootstrap analyses. In
nadjusted HRs/3-U Change in theummed Stres Score for Different OutcomesTable 4 Unadjust d HRs/3-U Change in theSummed Stress Score for Different Outcomes
Outcome HR/3-U 95% CI p Value
SCD 1.23 1.14–1.32 0.0001
Cardiovascular death 1.18 1.14–1.22 0.0001
Death other than SCD 1.07 1.05–1.10 0.0001
All-cause mortality 1.09 1.06–1.12 0.0001
ed stress score (SSS) of 8 or more
beneath the x-axis.summ
shownbbreviations as in Tables 1 and 2.
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July 13, 2010:206–14 SPECT and Sudden Death With LVEF >35%00 bootstrap samples, the LVEF was retained in 100 samples,
he Charlson index in 78, the SSS in 76, hypertension in 72,
ntiarrhythmic drug therapy in 53, and smoking in 53. The
-index of the overall predictive model was stable after correct-
ng for bias (0.72, 95% CI: 0.68 to 0.76).
CD risk prediction tool. With the beta coefficients from
ur multivariable Cox model, we constructed a SCD risk
rediction tool. In the nomogram, points are apportioned for
ncreasing SCD risk, as reflected by: declining LVEF, increas-
ng SSS, increasing Charlson index as well as antiarrhythmic
rug treatment, hypertension, and smoking (Table 5). For
xample, a patient with an SSS  10, hypertension, prior
istory of smoking, antiarrhythmic drug treatment, Charlson
ndex of 4, and an LVEF of 40% would have a point total of
66, which corresponds to a projected 5-year SCD rate of 30%.
rojected SCD rates at 3, 5, and 10 years are numerated in
able 6 and shown graphically in Figure 3.
isk reclassification. To assess the clinical implications of our
odel, we conducted a risk reclassification analysis (Table 7).
ccording to current guidelines, patients with CAD and an
VEF 35% are not candidates for primary prevention ICD
mplantation. Therefore, by default, these patients are currently
ategorized as low-risk in clinical practice. With our SPECT
CD nomogram described in the preceding text, we reclassi-
ed the cohort into low-risk (n 4,839) and high-risk groups
n  26). High-risk was defined as a 3-year predicted SCD
isk10%. The event rate was more than 4-fold greater in the
PECT-nomogram derived high-risk group. Among the 26
igh-risk patients identified by the combined SPECT nomo-
ram, 2 sustained an SCD event. Alternatively, the nomogram
ailed to identify 77 of the 79 SCDs as high-risk. Formal
ssessments with the NRI and IDI failed to show statisti-
PECT SCD NomogramTable 5 SPECT SCD Nomogram
SSS Points SSS Points
Charlson
Index Points EF Points
1 2 19 31 1 11 34 57
2 3 20 33 2 22 36 52
3 5 21 34 3 33 38 48
4 7 22 36 4 44 40 43
5 8 23 37 5 56 42 38
6 10 24 39 6 67 44 33
7 11 25 41 7 78 46 29
8 13 26 42 8 89 48 24
9 15 27 44 9 100 50 19
10 16 28 46 52 14
11 18 29 47 54 10
12 20 30 49 56 5
13 21 31 50
14 23 32 52
15 24 33 54
16 26 34 55 Antiarrhythmic 28
17 28 35 57 Hypertension 21
18 29 36 59 Smoking 14B
PECT  single-photon emission computed tomography; SSS  summed stress score; other
bbreviations as in Table 1.ally significant reclassification: NRI  0.0203 (p  0.26),
nd IDI  0.001 (p  0.38).
iscussion
here are 3 important findings from our analysis. First, among
atients with CAD and LVEF35%, stress MPI defects were
ssociated with an increased risk of SCD. Second, MPI added
ncremental prognostic information to the clinical history and
VEF for the prediction of SCD. Finally, we constructed a
isk prediction tool that uses LVEF, stress SPECT MPI
esults, and clinical risk factors to identify patients with an
VEF 35% at high risk of SCD.
Most SCD events occur in patients with LVEF35% (22).
reviously, we have shown that abnormal myocardial perfusion
s associated with SCD and provides incremental prognostic
nformation beyond the LVEF (23). In the current study, we
xamined the association between MPI and SCD in 4,865
atients with angiographically confirmed CAD and LVEF
35%. In this cohort, after adjustment for baseline character-
stics, including coronary revascularization and beta-blocker
herapy, the SSS (a global index of total extent and severity of
erfusion abnormality) was associated with an increase in the
azard of SCD. Patients with an SSS 8 had a lower
ncidence of SCD (log rank p  0.0001). Interestingly, the
RS and SDS were not independently associated with an
ncreased hazard of SCD, suggesting that in this mostly
reserved LVEF population, the presence of both “myocardial
car” and ischemia was a more potent driver of sudden death
isk than reversible ischemia or scar alone. Ischemia is a
ell-recognized risk factor for both recurrent ventricular ar-
hythmias and SCD (24,25). The 1 randomized controlled
rial of ICD therapy in patients who were newly revascularized
ailed to demonstrate a mortality benefit, again illustrating the
rominence of ischemia in the pathophysiology of SCD (26).
CD Rates Across SPECT Nomogram ScoresTable 6 SCD Rates Across SPECT Nomogram Scores
3-Yr SCD Rate 5-Yr SCD Rate 10-Yr SCD Rate
Total
Points
Risk of
SCD
Total
Points
Risk of
SCD
Total
Points
Risk of
SCD
137 0.10 119 0.10 94 0.10
144 0.12 136 0.15 111 0.15
151 0.14 148 0.20 123 0.20
157 0.16 158 0.25 133 0.25
162 0.18 167 0.30 142 0.30
166 0.20 174 0.35 149 0.35
171 0.22 181 0.40 156 0.40
174 0.24 187 0.45 162 0.45
178 0.26 168 0.50
181 0.28 173 0.55
185 0.30 179 0.60
188 0.32 184 0.65
191 0.34 189 0.70
194 0.36
bbreviations as in Tables 1 and 2.y contrast, hibernating myocardium (which can manifest as a
r
a
a
a
p
a
d
m
m
a
s
c
I
o
a
a
p
P
E
S
P
(
i
L
P
c
s
f
s
p
i
c
2
n
s
I
r
e
n
m
3MR
L
e
212 Piccini et al. JACC Vol. 56, No. 3, 2010
SPECT and Sudden Death With LVEF>35% July 13, 2010:206–14esting perfusion defect) is also a prominent risk substrate for
rrhythmogenesis and sudden death (27,28). Further studies
re needed to clarify the relative contribution of ischemia, scar,
nd even hibernating myocardium to SCD risk.
Prior reports have examined factors associated with SCD in
atients with CAD and preserved LV function. Al-Khatib et
l. (29) examined SCD events in nearly 2,000 patients with
iastolic heart failure (LVEF 50%) and found that diabetes,
itral regurgitation, NYHA functional classification, prior
yocardial infarction, and CAD severity were associated with
n increased risk of SCD. Although their analysis was re-
tricted to patients with an LVEF 50%, their cohort was
omposed entirely of patients with symptomatic heart failure.
n this analysis, where only 16% of the patients had a diagnosis
Figure 3 Projected SCD Rates Across SPECT Nomogram Score
A multivariable Cox model was used to generate a sudden cardiac death (SCD) no
by: declining left ventricular ejection fraction, increasing summed stress score, inc
at 3, 5, and 10 years according to the nomogram are illustrated here.
-Year Risks for SCD as Predicted byodels That Do and Do Not Inclu eesting Myoca dial Perfusion Data
Table 7
3-Ye r Risks for SCD as Predicted by
Models That Do and Do Not Include
Resting Myocardial Perfusion Data
Risk Scheme 2
(SPECT Nomogram) Frequency
Risk Scheme 1
(Current Clinical Practice)
Total
Low Risk
(LVEF >35%)
High Risk
(LVEF <35%)
Subjects who experience SCD
10% 77 0 77
10% 2 0 2
Total 79 0 79
Subjects who do not experience SCD
10% 4,762 0 4,762
10% 24 0 24
Total 4,786 0 4,786a
VEF  left ventricular ejection fraction; SCD  sudden cardiac death; SPECT  single-photon
mission computed tomography.f heart failure, the Charlson comorbidity index, hypertension,
ntiarrhythmic drug therapy, and smoking were independently
ssociated with the occurrence of SCD.
Prediction of SCD remains challenging, especially among
atients with LVEF 35%. Previously, investigators from the
EACE (Prevention of Events with Angiotensin Converting
nyzyme Inhibition) trial examined factors associated with
CD in 8,290 patients with CAD and LVEF40% (30). The
EACE investigators identified current angina, LVEF50%
vs. 50%), diuretic use, and digitalis therapy as factors
ndependently associated with SCD. Our analysis identified
VEF but not angina as a predictor of SCD. Additionally, the
EACE investigators constructed a risk prediction model that
ould identify patients with a 2.2%/year risk of SCD. With a
imilar population we constructed a nomogram with clinical
actors, LV function, and extent of perfusion abnormality by
tress SPECT MPI. With this nomogram, 3-year SCD
rojections range between 10% and 36% (Table 6). To put this
n perspective, the SCD event rate in the MADIT II (Multi-
enter Automatic Defibrillator Implantation Trial) was 11% at
years and 18% at 3 years (31). Therefore, our SPECT
omogram identifies patients with a projected risk of SCD
imilar to randomized trial populations shown to benefit from
CD insertion.
Although few patients with an LVEF 35% have a high-
isk profile, they still outnumber the low-LVEF SCDs in
pidemiologic studies, owing to the significantly larger “de-
ominator” of patients with LVEF 35% (32). Although our
odel only identifies a small fraction of LVEF35% patients
m. In the nomogram, points are apportioned for increasing SCD risk, as reflected
g Charlson index, as well as hypertension and smoking. The projected SCD ratess
mogra
reasint sufficiently high risk to merit possible interventions to
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July 13, 2010:206–14 SPECT and Sudden Death With LVEF >35%revent SCD, given the overall prevalence of CAD with EF
35%, our results have significant clinical implications.
When compared with a model based upon clinical factors
nd LVEF, the model incorporating SPECT stress perfu-
ion data provided incremental prognostic information as
eflected by the improvement in the global chi-square.
lthough receiver-operator characteristics and c-indexes
hould be viewed cautiously in the setting of risk prediction
odels (as opposed to diagnostic testing) (33), the c-index
or our model (0.728) exceeds the discriminatory accuracy of
idely used risk stratification tools, including the Throm-
olysis In Myocardial Infarction risk score for mortality/
eath/myocardial infarction in non–ST-segment elevation
cute coronary syndromes (c-index  0.63) (34) and the
HADS2 score (c-index  0.58) (35) for the prediction of
troke in patients with nonvalvular atrial fibrillation.
Recently, risk reclassification tables have been identified as a
ore intuitive and clinically useful way to ascertain the risk
tratification properties of a model (36). When we examined
he risk stratification of our population with conventional
riteria versus our combined nomogram, we found that only
.5% of the cohort was identified as “high risk.” However, if
hese patients were treated with ICD therapy the number
eeded to prevent 1 sudden death would have been approxi-
ately 13, a figure consistent with prior randomized trials of
CD therapy for low-LVEF populations (e.g., 17 in MADIT
I) (3). By contrast, the nomogram failed to identify 77 of the
9 patients who experienced SCD.
Formal assessment of our nomogram with the NRI and
DI failed to show statistically meaningful risk reclassifica-
ion. One potential limitation of risk reclassification analysis
s the dependence on the categories of risk used in the
odel. This was further complicated in our analysis, because
ur model only addressed increased risk (e.g., moving from
ow risk to high risk). Finally, although our nomogram was
esigned to be applied to a population with a range of
VEF 35%, most of the patients in this study had an
VEF 50%. Therefore, selection of different risk thresh-
lds or the application of our model in a population with
reater LV dysfunction (e.g., median LVEF 40% to 45%)
ight have yielded different results.
Finally, we would like to emphasize that we are not
dvocating that SPECT MPI serve as a de novo, stand-alone
creening tool. However, in patients who have SPECT MPI
erformed, attention should be paid to those patients with
erfusion characteristics associated with a high risk of SCD.
oving forward, optimal risk stratification will likely employ
ultiple risk markers, including LV function, myocardial
erfusion, genomics, and markers of autonomic dysfunction.
tudy limitations. The main limitations of this study are
he observational nature of the analysis and selection bias.
herefore, our results must be viewed as hypothesis-
enerating only. However, the association between the
PECT perfusion defects and SCD remained significant
fter extensive adjustment for clinical covariates, severity of
AD, and LV function. Although we adjusted for phar-acotherapy, including beta-blockade and antiarrhythmic
rugs at baseline, we could not account for changes in
harmacotherapy over time. In addition, clinical character-
stics and SPECT perfusion data were collected prospec-
ively, in consecutive patients, as part of routine clinical care,
hus limiting sampling and diagnostic bias. Another limi-
ation is that, despite quantification of LV function, LVEF
etermination was not uniform and represented several
maging modalities, including angiography, SPECT, and
chocardiography. Nonetheless, there was no association
etween the source of LVEF determination and SCD in
djusted analysis (p  0.15).
Although cause of death was adjudicated with standard,
alidated criteria, we cannot exclude the possibility of misclas-
ification bias, which could weaken the strength of the associ-
tion between prognostic variables and SCD. The list of
andidate variables included many known risk factors for SCD;
owever, other variables known to be associated with SCD
ere unavailable, including electrocardiography data (e.g., QT
nterval) and heart rate variability. Entry into the cohort
equired angiography and70% stenosis in at least 1 vessel. As
uch, the results cannot be directly applied to all patients
aving SPECT studies. Patients who are referred for angiog-
aphy afterward or in conjunction with SPECT examination
ypically represent a higher-risk population. Although our
redictive model was stable in bootstrap analysis, it should be
iewed with caution, because it has a modest c-index and has
ot yet been validated in an external CAD population. Model-
uilding procedures always involve the possibility of overfitting
r underfitting without external validation. Despite these
imitations, given the large number of patients, the wide range
f CAD severity in this cohort, the prospective data collection,
nd the strict definition and adjudication of SCD, the results
re not likely to be spurious.
onclusions
mong patients with CAD and preserved LV function,
PECT MPI defects are associated with an increased risk of
CD. SPECT perfusion imaging adds incremental prog-
ostic information to the clinical history for the prediction
f SCD. Further validation of these findings and prospec-
ive studies should address the role of SPECT perfusion
maging for the risk stratification of SCD in patients with
AD and LVEF 35%.
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